8-K current report · filed Nov 16, 2026

CorMedix Inc. (CRMD) 8-K Current Report: November 16, 2026

Item 7.01Item EX-99.1CRMD overview

Short answer

CorMedix Inc. (CRMD) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Conference call discussed CorMedix’s financial results for quarter ended September 30, 2026.

CorMedix Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Conference call discussed CorMedix’s financial results for quarter ended September 30, 2026
  • Full investor-call transcript furnished as Exhibit 99.1, containing management commentary and financial-results details
  • Proposed acquisition of substantially all Heron assets remains subject to Heron stockholder approval and required regulatory clearances
  • Transaction would issue CorMedix common stock to Heron through a private placement, creating potential shareholder dilution
  • Management highlights four FDA-approved commercial brands and anticipated revenue diversification, synergies and earnings accretion as transaction rationale

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $54.5M, down from $104.3M, reflecting DefenCath pricing pressure after post-TDAPA transition
  • DefenCath sales $17.2M, with dialysis utilization largely maintained at the $2.37 add-on rate
  • Heron assets expected to add $125M-$150M revenue in pro forma 2027 and $45M-$60M annual operating synergies by end-2027
  • FY2026 revenue guidance maintained at $325M-$345M, while adjusted EBITDA guidance narrowed to $130M-$140M
  • 2027 DefenCath guidance deferred amid quarterly reimbursement uncertainty and ongoing Medicare Advantage contracting

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other CorMedix Inc. 8-K filings

Get the next CRMD 8-K as it lands

Follow CRMD for push alerts, or ask the research agent what this filing means.